England eliminates prescription copay for cancer patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

Cancer patients in England will no longer have to pay prescription charges for medicines that treat their side effects, starting in April. Drugs that will be exempt include those that address pain, nausea, chronic diarrhea, fatigue, and mouth ulcers. Tamoxifen and other long-term hormone treatments are also currently subject to this charge.

Cancer patients in England will no longer have to pay prescription charges for medicines that treat their side effects, starting in April. Drugs that will be exempt include those that address pain, nausea, chronic diarrhea, fatigue, and mouth ulcers. Tamoxifen and other long-term hormone treatments are also currently subject to this charge.

Most medicines prescribed outside of hospitals by National Health Service (NHS) doctors are subject to a fixed charge of £7.10 (about $10.00) per item. Currently, patients being treated under the auspices of the NHS pay nothing for intravenous or oral chemotherapy drugs, analgesics, or antiemetics that are used during therapy sessions.

Cancer patients in England only (not the UK in general) can apply for a certificate that will exempt them from paying charges for prescription drugs for five years. They will remain eligible for free prescriptions even if they get the “all clear” before the five-year period is up. Th e exemption certificate can be renewed as many times as necessary, and it can be used when collecting any medicine prescribed by a general physician.

Up to 150,000 people already diagnosed with cancer stand to benefit from the scheme at an estimated cost to the NHS of £15 million ($21.5 million).

Government officials want to balance this loss of revenue by making greater use of generic products and by bulk-buying drugs more often.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content